Reactivation of pituitary hormone release and metabolic improvement by infusion of growth hormone-releasing peptide and thyrotropin-releasing hormone in patients with protracted critical illness

Journal of Clinical Endocrinology and Metabolism

Volumn 84, Issue 4, 1999, Pages 1311-1323

  Van Den Berghe, Greet ^a   Wouters, Pieter ^a   Weekers, Frank ^a   Mohan, Subburaman ^b   Baxter, Robert C ^c   Veldhuis, Johannes D ^d   Bowers, Cyril Y ^e   Bouillon, Roger ^a  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b LOMA LINDA UNIVERSITY   (United States)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

^e TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GROWTH HORMONE; INSULIN; LEPTIN; OSTEOCALCIN; PRALMORELIN; PROTIRELIN; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C;

ADULT; AGED; ARTICLE; BONE TURNOVER; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPOPHYSIS THYROID SYSTEM; INSULIN BLOOD LEVEL; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTRACTED CRITICAL ILLNESS; RANDOMIZED CONTROLLED TRIAL; THYROID HORMONE BLOOD LEVEL; TREATMENT OUTCOME;

EID: 0033344431     PISSN: 0021972X     EISSN: None     Source Type: Journal    
DOI: 10.1210/jc.84.4.1311     Document Type: Article

References (54)

1. Aggressive nutritional support does not prevent protein loss despite fat gain in septic intensive care patients
2. A descriptive study of skeletal muscle metabolism in critically ill patients: Free amino acids, energy-rich phosphates, protein, nucleic acids, fat, water, and electrolytes
3. The somatotropic axis in critical illness: Effect of continuous GHRH and GHRP-2 infusion
4. Neuroendocrinology of critical illness: Effect of continuous thyrotropin-releasing hormone infusion and its combination with growth hormone-secretagogues
5. Acute and chronic critical illness as different neuroendocrine paradigms
6. Pituitary responsiveness to growth hormone (GH) releasing hormone, GH-releasing peptide-2 and thyrotropin releasing hormone in critical illness
7. On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone
8. A receptor in pituitary and hypothalamus that functions in growth hormone release
9. Thyrotropin and prolactin release in prolonged critical illness: Dynamics of sponaneous secretion and effects of growth hormone secretagogues
10. Growth hormone secretion in critical illness: Effect of doparnine
11. Doparnine and the sick euthyroid syndrome in critical illness
12. Anterior pituitary function during critical illness and doparnine treatment
13. APACHE II: A severity of disease classification system
14. Nutritional support
15. Alterations in carbohydrate metabolism during stress: A review of the literature
16. Relationship between baseline insulin-like growth factor-I (IGF-I) and femoral bone density in women aged over 70 years: Potential implications for the prevention of age-related bone loss
17. Age-related (type II) femoral neck osteoporosis in men: Biochemical evidence for both hypovitaminosis D- and androgen deficiency-induced bone resorption
18. Diurnal rhythm of growth hormone-independent binding protein for insulin-like growth factors in human plasma
19. Radioimmunoassay of growth hormone-dependent insulin-like growth factor binding protein in human plasma
20. Circulating levels and molecular distribution of the acid-labile (α) subunit of the high molecular weight insulin-like growth factor-binding protein complex in normal subjects
21. Recombinant synthesis insulin-like growth factor binding protein-4 (IGFBP-4): Development, validation and application of a radioimmunoassay for IGFBP-4 in human serum and other biological fluids
22. Development, validation and application of a radioimmunoassay for insulin-like growth factor binding protein-5 in human serum and other biological fluids
23. Homologous radioimmunoassay of human osteocalcin
24. Time-related increase of biochemical markers of bone turnover in androgen-deficient male rats
25. Determination of serum creatinine by a direct colometric method
26. Influence of the vitamin D-binding protein on the serum concentration of 1,25-dihydroxyvitamin D(3): Significance of the free 1,25-dihydroxyvitamm D(3) concentrafion
27. Deconvolution analysis of pulsatile hormone data
28. Disordered renal function: Diagnosis
29. Relationship of cell growth to regulation of tissue-specific gene expression during osteoblast differentiation
30. Influence of age, sex, and insulin on osteoblast function: Osteoblast dysfunction in diabetes mellitus
31. Protein metabolism in the traumatized patient
32. Response of the bowel to the injury and the transition from parenteral to enteral feedings
33. Increased urinary excretion of pyridinium cross-links in cancer patients
34. Evaluation of urinary hydroxypyridium crosslink measurement as resorption markerts in metabolic bone diseases
35. Urinary hydroxypyridinium crosslinks of collagen in pomulation-based screening for overt vertebral osteoporosis: Results of a pilot study
36. Urinary pyridinium cross-link excretion is increased in critically ill surgical patients
37. Luteinizing hormone secretion and hypoandrogenemia in critically ill men: Effect of dopamine
38. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor-necrosis factor via its P55 receptor
39. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans
40. Insulin-like growth factor (IGF)-binding protein-5 forms an alternative ternary complex with IGF's and the acid-labile subunit
41. Studies on the mechanisms by which insulin-like growth factor binding protein-4 (IGFBP-4) and IGFBP-5 modulate IGF actions in bone cells
42. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy
43. Evidence for a novel insulin-like growth factor (IGF)-dependent protease regulating IGF-binding protein-4 in dermal fibroblasts
44. Decreased hypothalamic thyrotropin-releasing hormone gene expression in patients with non-thyroidal illness
45. Leptin levels in protracted critical illness: Effects of growth hormone-secretagogues and thyrotropin-releasing hormone
46. Multihormonal control of ob gene expression and leptin secretion from cultured human visceral adipose tissue: Increased responsiveness to glucocorticoids in obesity
47. The acute and chronic effect of growth hormone (GH) treatment on leptin in GH deficiency: Relationship to body composition, IGF-I and insulin
48. Effects of prolonged hyperinsulinemia on serum leptin in normal human subjects
49. Effect of recombinant human IGF-I therapy on plasma leptin
50. Direct antidiabetic effect of leptin through triglyceride depletion of tissues
51. Leptin in anorexia nervosa
52. Growth hormone and bone
53. Leptin acts on human marrow stromal precursor ceils to enhance osteoblast differentiation and to inhibit adipocyte differentiation: A potential mechanism for increased bone mass in obesity
54. Neuroendocrine alterations in the somatotropic and lactotropic axes in uremic men